China Securities Network News (Wang Luo) On the evening of December 1, Huasen Pharmaceutical disclosed that recently, the State Drug Administration issued the "Announcement on the Extension of the Protection Period of Protected Varieties of Traditional Chinese Medicine No. 13" (No. 152 of 2023), approving the company's production of sweet orange ice plum slices to continue to give secondary protection to the protected varieties of traditional Chinese medicine, the protected variety number: ZYB20720230130, extending the protection period to January 19, 2030.
According to the announcement, Ganju Bingmei Pian is the company's exclusive Chinese patent medicine, which has outstanding curative effects on dry throat, sore throat, hoarseness, pharyngeal mucosal congestion, etc., and has a variety of effects such as clearing heat and detoxifying, reducing swelling and relieving pain, promoting lung phlegm, and moistening dryness, especially suitable for respiratory tract infections with sore throat, dry throat and hoarseness as the main characteristics, and can be anti-inflammatory, antibacterial, antiviral, swelling and pain relief. Ganju Bingmei Pian has entered the "Guidelines for Clinical Diagnosis and Treatment of Traditional Chinese Medicine Otolaryngology", "Guidelines for the Clinical Application of Chinese Patent Medicines - Otolaryngology Diseases", "Expert Consensus on Health Management of Chinese Medicine at Home for Novel Coronavirus", "Expert Consensus on the Prevention and Treatment of Chinese Medicine in the Spring of 2023", the State Administration of Traditional Chinese Medicine "Two Guarantees and One Stability" List of Chinese Patent Medicines (** and the recommended drug guidelines or recommended drug lists of some provinces and cities such as Chongqing, Jiangsu Province, Sichuan Province, Henan Province, Fujian Province, etc., And in 2023, it will be included in the "100 Varieties of Traditional Chinese Medicine with Unique Efficacy Based on Evaluation Evidence" selected and released by relevant departments organized by the State Administration of Traditional Chinese Medicine.
The company said that the approval of the State Food and Drug Administration to continue to give the company's drug Ganqu Bingmei Tablets Level 2 protection will help continue to enhance the core competitiveness of the product and have a positive impact on the company's production and operation. However, due to the uncertainty of drug production and sales affected by factors such as pharmaceutical industry policies and market competition, investors should also pay attention to prevent investment risks.